Browse the corpus

Albuterol, also known as salbutamol, is approved by the U.S. Food and Drug Association (FDA) for treating and preventing acute or severe bronchospasm in patients with reversible obstructive airway disease, including exercise-induced bronchospasm. Albuterol is a commonly prescribed bronchodilator used for managing diverse respiratory conditions, including asthma and exercise-induced bronchospasm. This activity covers the appropriate indications, administration, contraindications, adverse drug reactions, and precautions associated with albuterol to ensure its safe and proper utilization. This activity also aims to equip healthcare professionals with a comprehensive understanding of albuterol therapy in obstructive airway diseases, allowing for efficient and effective drug use in clinical settings. Objectives: Identify appropriate indications for albuterol therapy, recognizing its role in treating acute or severe bronchospasm and preventing exercise-induced bronchospasm in patients with reversible obstructive airway disease. Implement proper administration techniques for different albuterol delivery systems, including aerosol metered-dose inhalers, nebulizers, and tablets, considering factors such as patient age, severity of symptoms, and comorbidities. Screen patients for contraindications and potential risks associated with albuterol, especially those with cardiovascular diseases or hypersensitivity reactions. Collaborate with other healthcare professionals, including physicians, immunologists, pharmacists, and nurses, to ensure a comprehensive, interprofessional approach to albuterol therapy. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose An albuterol dose of 1 mg/kg is potentially toxic for children 6 or younger. Similar to other β2-adrenergic receptor agonists, albuterol has been shown to cause an increase in liver aminotransferase concentrations on rare occasions. This specific toxicity reaction is more common in other β2-adrenergic receptor agonists, such as terbutaline, which is administered in much greater quantities, such as in the context of abating uterine contractions. Although overdose from inhaled albuterol is rare, recognizing the signs of albuterol toxicity is clinically significant. Management of Overdose Diagnosis relies on a comprehensive evaluation, combining clinical assessments and laboratory findings. Essential indicators include tremors, hypokalemia, hyperglycemia, and cardiac arrhythmias. Acute albuterol toxicity can result in lactic acidosis. β2-adrenergic stimulation increases cAMP-mediated gluconeogenesis and lipolysis, leading to elevated plasma glucose levels. Consequently, there is an increased conversion to pyruvate and lactate. In instances of albuterol toxicity, hyperventilation typically stems from a compensatory response to metabolic acidosis rather than an indication of worsening respiratory distress requiring an increased albuterol requirement. The management of albuterol-induced hypokalemia should be approached cautiously, as the underlying mechanism involves a transcellular shift rather than a total body potassium deficit. Treatment primarily involves supportive measures, including discontinuing the offending agent and managing arrhythmias according to ACLS protocol.[29]

All healthcare professionals, including physicians, physician assistants, and nurse practitioners who prescribe inhalers, should educate patients on the proper usage of medications. Using a face mask is crucial for children aged 4 or younger. Caution is necessary when treating patients with cardiovascular diseases, such as heart disease, as supratherapeutic albuterol may exacerbate heart failure with reduced ejection fraction. Close monitoring is essential for patients with diabetes mellitus, hyperthyroidism, hypokalemia, or glaucoma.[30] Clinicians initiate albuterol therapy for specific medical conditions or indications. Nurses and pharmacists play a critical role in patient care. Nurses educate patients on medicine usage, monitor their progress and compliance, and ensure their well-being. On the other hand, pharmacists demonstrate the proper use of inhalers, spacers, and nebulizers. Both nurses and pharmacists communicate openly with the clinician to address any concerns. An observational study examined patients with severe asthma, emphasizing specialist care provided by allergists, immunologists, and pulmonologists. The study revealed that only 38.2% of the 54,332 commercially insured individuals meeting severe asthma criteria received care from these specialists over 2 years. Factors associated with specialist visits included higher asthma exacerbation frequency, younger age, and a greater allergy or respiratory comorbidities burden. Following specialist care, there was a noticeable reduction in asthma exacerbations and rescue inhaler use. This highlights the potential benefits of increased specialist involvement in managing severe asthma, particularly among those with complex comorbidities.[31] An interprofessional healthcare team approach, characterized by open communication among physicians/advanced practice practitioners, immunologists, pharmacists, and nurses, can enhance patient outcomes associated with albuterol therapy while minimizing adverse effects.